Best Peptides for Fat Loss

Educational content only. Not medical advice. Weight management decisions involve significant medical considerations; consult a licensed healthcare provider.

Overview

Fat loss peptides are short chains of amino acids that influence the metabolic pathways governing appetite, energy expenditure, lipolysis, and glucose handling. Unlike traditional weight-loss drugs (stimulants, lipase inhibitors, serotonergic agents) — which produced modest results and frequently caused intolerable side effects — modern fat loss peptides have rewritten the landscape of obesity medicine.

There are two principal mechanism families to understand:

1. GLP-1 / incretin agonists — peptides that mimic gut hormones to reduce appetite, slow gastric emptying, and improve insulin signaling. This family includes the headline-grabbing best peptides for fat loss that most people search for: semaglutide, tirzepatide, retatrutide, and oral semaglutide.
2. Lipolytic peptides — peptides that act directly on adipose tissue or metabolic enzymes to promote fat oxidation, without significantly altering appetite. This family includes AOD-9604, HGH Fragment 176-191, 5-Amino-1MQ, and MOTS-c.

The reason weight loss peptides have eclipsed prior drug categories is mechanistic specificity. Where amphetamines forced calorie reduction through CNS arousal and orlistat blocked fat absorption (with predictable GI consequences), peptide therapy for weight loss harnesses the body's own regulatory hormones. The result is double-digit percentage weight loss in clinical trials — a magnitude previously only achievable through bariatric surgery.

This hub is the master reference for GLP-1 peptides and peptides for body recomposition. Below you'll find mechanism explanations, comparative protocols, realistic expectation tables, side effect profiles, monitoring frameworks, and direct links to deep-dive protocols on each individual compound.

The Two Families of Fat Loss Peptides

The peptide universe for fat loss splits cleanly into three operational categories. Understanding which category a peptide belongs to dictates how to use it, what to expect, and what to stack it with.

The headline-grabbing drugs — what most people mean by GLP-1 peptides — sit at the top of this table. They produce dramatic scale movement. The lipolytic and metabolic peptides at the bottom produce more modest scale movement but are useful for stubborn fat, recomposition, and as adjuncts.

For comprehensive protocols on each:

• Semaglutide complete guide
• Tirzepatide protocol
• Retatrutide protocol
• Oral semaglutide protocol
• AOD-9604 protocol
• Fragment 176-191 protocol
• 5-Amino-1MQ protocol
• Tesamorelin protocol

How GLP-1s Work (Semaglutide → Retatrutide)

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the gut after eating. Its natural role is to coordinate the post-meal metabolic response. GLP-1 peptides are pharmaceutical analogs that bind GLP-1 receptors and produce the same effects, but with a half-life measured in days instead of minutes.

The Three Mechanisms of GLP-1 Action

1. Central appetite suppression — GLP-1 receptors in the hypothalamus reduce hunger signaling. Many patients describe a quieting of "food noise" — intrusive thoughts about eating.
2. Delayed gastric emptying — Food sits in the stomach longer. Smaller meals produce sustained fullness.
3. Glucose-dependent insulin secretion — Pancreatic β-cells release insulin in response to glucose, but only when glucose is elevated. This is why GLP-1s rarely cause hypoglycemia in non-diabetics.

Why Dual and Triple Agonists Outperform Mono-Agonists

The mono-agonist semaglutide produces ~15% weight loss in trials (STEP-1, 68 weeks). Tirzepatide — a dual GLP-1/GIP agonist — pushes that to ~22% (SURMOUNT-1). Retatrutide adds glucagon receptor activation and shows ~24% in Phase 2.

The mechanistic reason: GLP-1 alone primarily reduces caloric intake. GIP activation adds metabolic flexibility (better fat oxidation in adipose tissue). Glucagon activation increases basal energy expenditure — the body actually burns more calories at rest. Each receptor adds an independent lever.

This is why retatrutide trial participants lose weight at a pace closer to bariatric surgery than to traditional medication. For the deepest dive on this progression, see the Retatrutide protocol guide and compare against the Tirzepatide protocol.

How Lipolytic Peptides Work (AOD-9604, Fragment 176-191)

Lipolytic peptides take a different — and far more localized — approach to fat loss. Where GLP-1s work top-down (reduce intake, slow digestion), lipolytic peptides work bottom-up: they signal adipocytes to release stored triglycerides for oxidation.

The β3-Adrenergic Pathway

Both AOD-9604 and HGH Fragment 176-191 are derived from the C-terminal end of human growth hormone — specifically, the lipolytic domain. They stimulate β3-adrenergic receptors on fat cells, triggering hormone-sensitive lipase and unleashing stored triglycerides into circulation.

What Makes These Peptides Different from HGH

Full HGH causes growth-promoting effects throughout the body via IGF-1 elevation: muscle anabolism, joint changes, organ growth, insulin resistance. The fragments preserve the fat-burning domain without elevating IGF-1 — effective only for fat metabolism, with no anabolic or recovery benefit.

Why Effects Are More Modest

A 12-week AOD-9604 trial showed roughly 2-3% body weight reduction — meaningful, but a fraction of GLP-1 magnitude. Lipolytic peptides don't reduce caloric intake; they merely mobilize stored fat. Without a caloric deficit, mobilized fat is re-esterified. This makes lipolytic peptides best suited as adjuncts to a structured diet, training program, and sometimes a low-dose GLP-1.

Detailed protocols:

• AOD-9604 protocol
• HGH Fragment 176-191 protocol
• AOD-9604 + Tesamorelin stack

Comparison: Which Peptide for Which Goal

Different goals demand different tools. The table below maps common scenarios to the most appropriate peptide or stack.

This framework is a starting point, not a prescription. Individual response varies — see the Realistic Expectations section below.

Realistic Expectations

Trial data and real-world data diverge. Clinical trials feature highly adherent participants, intensive support, and structured diet/exercise interventions. Real-world results are typically 30-50% lower than trial averages.

Clinical Trial Weight Loss (68-72 weeks, mean values)

Realistic Real-World Expectations

• Months 1-3: 5-8% body weight, mostly from appetite suppression
• Months 3-6: Continued loss at slower pace, total often 10-15%
• Months 6-12: Plateau common; final losses depend on dose, adherence, and lifestyle
• Beyond 12 months: Maintenance phase; weight regain begins if peptide is stopped abruptly

Sources of Individual Variability

• Baseline BMI — higher baseline = larger absolute losses, often smaller percentage losses
• Insulin sensitivity — insulin-resistant patients often respond more dramatically
• Compliance with titration — patients who can't tolerate dose increases stall earlier
• Protein intake and resistance training — body composition outcomes diverge sharply
• Sleep, stress, alcohol — significant modifiers of GLP-1 efficacy

Frame expectations around the lower end. If you'd be satisfied with 10% loss, you're unlikely to be disappointed.

Sample Protocols

The protocols below are illustrative frameworks based on clinical and community data, not prescriptions. Dosing should always be supervised by a qualified clinician.

Starter Protocol (Modest Loss, Recomposition Lean)

Goal: 5-8% body fat reduction, lean mass preserved. Good for people not ready for GLP-1.

Serious Weight Loss Protocol (Tirzepatide-Based)

Stack: Protein at 1g/lb LBM, resistance training 3x/wk, electrolytes. Full details in the Tirzepatide protocol.

Advanced Body Recomposition Stack

This is for experienced users with medical supervision. See the body recomposition protocol for the full framework.

Side Effects & Safety

Fat loss peptides — particularly GLP-1s — have a meaningful side effect profile. Most are dose-dependent and tolerable; some are serious.

Common (GLP-1 Class)

• Nausea — 40-60% incidence at therapeutic doses; usually transient over weeks
• Constipation or diarrhea — slowed gastric emptying alters bowel patterns
• Heartburn / reflux — food sits longer in the stomach
• Fatigue — especially early as caloric intake drops
• Decreased appetite (desired effect, but problematic if severe)
• Injection-site irritation — mild and self-limiting

Serious (Rare but Important)

• Acute pancreatitis — boxed warning consideration; presents as severe abdominal pain radiating to back
• Gallbladder disease — rapid weight loss increases gallstone risk
• Medullary thyroid carcinoma (MTC) — black box warning based on rodent studies; contraindicated in personal or family history of MTC or MEN-2
• Diabetic retinopathy progression — in some diabetic populations during rapid glucose normalization
• Severe hypoglycemia — rare in non-diabetics; common when combined with insulin or sulfonylureas
• Suicidal ideation / mood changes — reports under FDA investigation; relationship unclear

Lipolytic Peptide Side Effects

AOD-9604 and Fragment 176-191 have a remarkably clean side effect profile in trials — no IGF-1 elevation, no insulin resistance, no joint changes. Occasional injection-site reactions are the main complaint.

Absolute Contraindications for GLP-1s

Personal or family history of medullary thyroid carcinoma, MEN-2, prior pancreatitis, pregnancy or planned pregnancy (washout required), and severe gastroparesis.

Drug Interactions

GLP-1s slow gastric emptying, which changes the absorption kinetics of every oral medication taken with them.

Notable Interactions

• Oral contraceptives — absorption may be reduced; some clinicians recommend backup contraception during initiation and dose escalation
• Levothyroxine — narrow therapeutic window; check TSH 6 weeks after starting GLP-1
• Warfarin — INR can shift; monitor closely
• Insulin and sulfonylureas — increased hypoglycemia risk; doses typically need to be reduced
• Anticonvulsants — variable absorption changes; monitor levels if narrow therapeutic index
• NSAIDs — increased GI side effect burden
• Alcohol — amplified nausea, worsens appetite suppression effects

Surgery Considerations

Many anesthesiology societies now recommend holding GLP-1s for at least 1 week before elective surgery due to retained gastric contents and aspiration risk. Discuss with both your prescriber and surgical team well in advance.

The "Ozempic Face/Butt" Problem

Rapid fat loss — without proportional protein intake and resistance training — produces predictable cosmetic consequences: facial volume loss ("Ozempic face") and gluteal/limb soft-tissue loss ("Ozempic butt"). The underlying issue is that fat loss isn't the only loss happening.

What's Actually Going On

When you lose weight rapidly, you lose three things in parallel:

1. Subcutaneous fat (desired)
2. Lean body mass (undesired — typically 20-25% of weight lost is non-fat)
3. Skin and connective tissue elasticity (gradual; depends on age and rate)

The face and gluteal regions store both fat and muscle. Lose both quickly, and the structural support collapses. The skin doesn't retract proportionally.

How to Prevent It

1. Protein at 1g per lb of lean body mass — non-negotiable. For a 180lb person with 25% body fat, that's 135g protein daily.
2. Resistance training 3-4x per week — preserves and stimulates muscle protein synthesis. Cardio alone is insufficient.
3. Slower rate of loss — aim for 1% of body weight per week or less. Faster = more lean mass loss.
4. Creatine monohydrate — 3-5g daily; preserves muscle mass and water content.
5. Adequate caloric intake — don't combine maximum GLP-1 dose with severe self-imposed restriction. The peptide creates the deficit; further restriction creates malnutrition.
6. GH secretagogues — sermorelin, tesamorelin, CJC-1295 can preserve lean mass during weight loss. See GH peptide stacking.

What to Do When You Plateau

Almost every patient on GLP-1 therapy plateaus eventually. Common timing: months 4-9. The body adapts. Here's the playbook.

1. Confirm the Plateau Is Real

A 2-3 week stall is normal weight variability. Re-evaluate after 4+ weeks of stalled progress with consistent measurement.

2. Re-examine Compliance

Tracking food vs. eyeballing? Alcohol creeping up? Protein dropping because appetite is suppressed? Sleep adequate?

3. Dose Escalation

If you're below maximum tolerated dose, the next titration step often restarts progress.

4. Add a Lipolytic Peptide

This is where AOD-9604 or HGH Fragment 176-191 shine. The mechanism is independent of GLP-1, so it doesn't compete with tolerance. The AOD-9604 + Tesamorelin stack is purpose-built for this use case.

5. Strategic Refeed Days

Counterintuitive but effective: one calorie-maintenance day per week can restore leptin levels and break stalls. Not a binge — a planned maintenance day.

6. Intensify Resistance Training

More muscle = higher basal metabolic rate. Adding a 4th or 5th weekly session often resumes progress.

7. Switch Compounds

If you've been on semaglutide for 12+ months and plateaued, switching to tirzepatide is the most common next step. Different receptor profile = renewed response.

Maintenance After Stopping

The most important question for anyone starting GLP-1 therapy: what happens when I stop? Trial data is unambiguous.

The STEP-4 Trial Result

Patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. This is the foundational data point for understanding maintenance.

Why Rebound Happens

• Appetite returns — and often overshoots prior baseline
• "Food noise" returns
• Gastric emptying normalizes
• Metabolic adaptation persists (your body burns less at rest after weight loss)
• Behavioral patterns reassert

Maintenance Strategies

Option 1: Indefinite Low-Dose Maintenance Increasingly the standard. Drop to the lowest dose that maintains weight (often 0.25-0.5mg/wk semaglutide or 2.5-5mg/wk tirzepatide). Treat obesity as a chronic condition requiring chronic medication, just like hypertension.

Option 2: Gradual Taper + Lifestyle Lock-In Slowly reduce dose over 6-12 months while aggressively cementing habits: protein target, training schedule, sleep, alcohol limits. Some patients sustain this; most regain.

Option 3: Bridge to Lipolytic Peptides Some clinicians taper GLP-1 while adding AOD-9604 or tesamorelin as a maintenance bridge — lipolytic peptides don't reduce appetite but can sustain body composition during wash-out.

The honest answer for most patients: plan for indefinite use unless lifestyle changes allow safe withdrawal under medical supervision.

Bloodwork & Monitoring

Comprehensive bloodwork before, during, and after fat loss peptide therapy isn't optional — it's the difference between safe optimization and undetected problems. See the broader bloodwork checklist for a full panel.

Baseline Panel (Before Starting)

• CBC — complete blood count
• CMP — comprehensive metabolic panel including kidney and liver function
• HbA1c + fasting glucose — baseline glucose status
• Fasting insulin + C-peptide — insulin sensitivity baseline
• Lipase + amylase — pancreatic baseline (critical given pancreatitis risk)
• TSH, free T3, free T4 — thyroid baseline
• Lipid panel — total cholesterol, LDL, HDL, triglycerides
• CRP (hs-CRP) — inflammation baseline
• Vitamin D, B12, ferritin, iron panel — nutrient status
• Calcitonin — only if MTC/MEN-2 concern

Week 12 Recheck

• Repeat CMP, HbA1c, lipid panel, lipase, TSH
• If symptoms suggest pancreatitis, lipase immediately

Ongoing (Every 6 Months on Therapy)

• HbA1c, fasting glucose, lipids, lipase, kidney function
• Annual full panel
• DXA scan if available — tracks body composition vs. just weight

What to Watch For

• Lipase rising 2-3x baseline → pause, evaluate for pancreatitis
• Rapid TSH change → adjust thyroid medication if applicable
• Falling B12 → common with reduced food intake; supplement
• Worsening LFTs → uncommon but investigate
• Severe muscle mass loss on DXA → indicates training/protein inadequate

Cost & Insurance

Cost is the largest practical barrier for most patients. Pricing is volatile in 2026, but rough benchmarks:

Branded (Cash Pay, No Insurance)

Compounded (US Compounding Pharmacies)

• Compounded semaglutide: $200-400/month (declining as FDA shortage resolution proceeds)
• Compounded tirzepatide: $300-500/month (similar regulatory pressure)
• Retatrutide (research only): variable

The FDA shortage list determines whether 503A and 503B pharmacies can legally compound these drugs. As of mid-2026, the regulatory landscape is shifting — always verify your pharmacy's compliance. See vendor red flags and the compounding pharmacy guide.

Insurance Gotchas

• Most commercial insurance covers GLP-1s for type 2 diabetes but not for weight management alone
• Medicare currently does not cover GLP-1s for obesity (under legislative review)
• BMI thresholds, prior authorization, and "step therapy" requirements are nearly universal
• Some employers carve out weight management coverage entirely

Lipolytic Peptide Costs

AOD-9604, HGH Fragment 176-191, 5-Amino-1MQ are typically $80-200/month from research peptide vendors. Always verify COA (certificate of analysis) — see the COA reading guide.

Stacking Considerations

Fat loss peptides rarely operate in isolation. Thoughtful stacking amplifies results and mitigates downsides.

Stack 1: GLP-1 + BPC-157 (Gut Protection)

GLP-1s slow gastric emptying and can stress GI motility. BPC-157 (250 mcg daily) protects the gut lining and may reduce nausea, reflux, and constipation. Particularly useful during titration phases.

Stack 2: GLP-1 + GH Secretagogue (Lean Mass Preservation)

Adding sermorelin, tesamorelin, or CJC-1295/ipamorelin during a GLP-1 protocol can preserve lean mass via pulsatile GH release. The lipolytic effect compounds favorably with the GLP-1 appetite suppression. Full framework in the GH peptide stacking guide.

Stack 3: Lipolytic + Resistance Training (Body Recomp)

AOD-9604 + a structured training program is the gold standard for shedding stubborn fat while building/preserving muscle. Without training, the lipolytic peptides are wasted potential.

Stack 4: Tesamorelin + AOD-9604 (Visceral Fat Focus)

The AOD-9604 + Tesamorelin stack addresses visceral fat (tesamorelin is FDA-approved for this) alongside subcutaneous fat (AOD-9604's domain). The most evidence-based pure-lipolytic stack.

Non-Negotiable Companions for Any Fat Loss Stack

• Resistance training — 3-5 sessions weekly, mandatory
• Protein — 1g per lb LBM daily
• Sleep — 7-9 hours; sleep loss tanks GLP-1 efficacy
• Hydration — GLP-1s blunt thirst cues
• Electrolytes — sodium, potassium, magnesium during rapid weight loss

Top 10 Fat Loss Peptide FAQ

1. What are the best peptides for fat loss? For weight loss magnitude, the answer is tirzepatide and retatrutide. For body recomposition with minimal side effects, AOD-9604 + tesamorelin. The "best" depends on your goal, baseline, and tolerance. See the Tirzepatide protocol and Retatrutide guide.

2. How much weight can I expect to lose on semaglutide vs tirzepatide? Trial data: semaglutide ~15%, tirzepatide ~22% over ~68 weeks at maximum doses. Real-world outcomes typically run 30-50% lower due to adherence and lifestyle factors. Read the Semaglutide complete guide for full data.

3. Do peptides like AOD-9604 actually work? Yes — but modestly. AOD-9604 produces ~2-3% body weight reduction in trials and works best as an adjunct to diet, training, and sometimes a low-dose GLP-1. It will not produce GLP-1-magnitude results on its own. Full mechanism in the AOD-9604 protocol.

4. Will I regain weight when I stop GLP-1 peptides? Likely yes. STEP-4 data: ~two-thirds of lost weight returns within a year. Plan for indefinite low-dose maintenance or aggressive lifestyle replacement.

5. Are oral GLP-1s as effective as injectable? Oral semaglutide (Rybelsus) at 50mg has shown ~15% weight loss in trials — comparable to injectable semaglutide. The dosing is more finicky (fasted, water only, 30-minute wait). Full details in the oral semaglutide protocol.

6. Can I stack GLP-1s with other peptides? Yes — common stacks include BPC-157 (gut protection), tesamorelin (visceral fat), and AOD-9604 (lipolysis). Avoid stacking with anything that adds GI side effects.

7. What's the difference between Fragment 176-191 and AOD-9604? Both are HGH fragments targeting the lipolytic domain. AOD-9604 is a modified form developed for stability. In practice, effects are similar; AOD-9604 has slightly more clinical data. Compare in the Fragment 176-191 protocol.

8. Is 5-Amino-1MQ safe for fat loss? 5-Amino-1MQ is a novel NNMT inhibitor with promising preclinical data and emerging human use. Long-term safety data is limited. Treat as experimental. See the 5-Amino-1MQ protocol.

9. How do I avoid muscle loss while losing fat with peptides? Three rules: 1g protein per lb LBM daily, 3-5 resistance training sessions weekly, slower rate of loss (~1% body weight/week or less). Optionally add a GH secretagogue.

10. Are compounded GLP-1s safe? Quality varies dramatically by pharmacy. Stick to 503A or 503B pharmacies with cGMP compliance, COAs available on request, and verifiable licensing. The vendor scorecard framework walks through evaluation.

Featured Protocols on Peptides.NYC

For deep dives on every fat loss peptide referenced in this hub:

GLP-1 / Incretin Agonists

• Semaglutide: The Complete Protocol Guide
• Tirzepatide (Mounjaro): Dual-Agonist Protocol
• Retatrutide: Triple Agonist Phase 3 Guide
• Oral Semaglutide (Rybelsus): Complete Guide

Lipolytic Peptides

• AOD-9604: The Fat Loss Fragment Protocol
• HGH Fragment 176-191: Targeted Fat Loss

Metabolic Enhancers

• 5-Amino-1MQ: NNMT Inhibitor Protocol

Stacks and Combination Protocols

• Body Recomposition Protocol
• AOD-9604 + Tesamorelin: Ultimate Fat Loss Stack
• Tesamorelin: FDA-Approved GH Protocol

Reminder: This hub is educational content only. Peptide therapy for weight loss involves prescription medications, real medical risks, and individual factors that require professional evaluation. Work with a licensed clinician before starting any protocol.